

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 56992

Manuscript Type: CASE REPORT

Roxadustat for the treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report

Wei-Hong Yu, Xie-Jia Li, Fang Yuan

Abstract

BACKGROUND

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is a prevalent problem in patients with chronic kidney disease. It is associated with increased morbidity and mortality in patients who undergo dialysis. A significant proportion of patients do not

Match Overview

1	Crossref 52 words Mario Bonomini, Lucia Del Vecchio, Vittorio Sirolli, France ... o Locatelli. "New Treatment Approaches for the Anemia of	2%
2	Internet 41 words crawled on 08-Aug-2020 www.wjgnet.com	2%
3	Internet 38 words crawled on 10-Aug-2019 academic.oup.com	1%
4	Internet 36 words crawled on 29-Nov-2019 epdf.pub	1%
5	Crossref 30 words Juan M. López-Gómez, José M. Portolés, Pedro Aljama. "F actors that condition the response to erythropoietin in pati ...	1%
6	Internet 21 words crawled on 01-Mar-2020 www.jci.org	1%
7	Internet 21 words crawled on 04-Jun-2017 www.rbhh.org	1%
8	Internet 20 words crawled on 02-May-2020 onlinelibrary.wiley.com	1%



ALL

IMAGES

VIDEOS

98,400 Results

Any time ▾

Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901713>

Jul 24, 2019 - Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data ...

Cited by: 77

Author: Nan Chen, Chuanming Hao, Bi-Cheng Liu...

Publish Year: 2019

Roxadustat for Anemia in Patients with Kidney Disease Not ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1813599>

Jul 24, 2019 - Roxadustat and Anemia of Chronic Kidney Disease J. Kaplan; Original Article Sep 12, 2019 Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis ...

Cited by: 103

Author: Nan Chen, Chuanming Hao, Xiaomei Pen...

Publish Year: 2019

Roxadustat for Anemia in Patients with Chronic Kidney ...

<https://www.nejm.org/doi/full/10.1056/NEJMc1913712>

To the Editor: Chen et al. (Sept. 12 issue) 1 report that in their trial of roxadustat (FGCL-4592-808) in patients with chronic kidney disease who were not undergoing dialysis, roxadustat was more...

Roxadustat and Anemia of Chronic Kidney Disease | NEJM

<https://www.nejm.org/doi/full/10.1056/NEJMe1908978>

Jul 24, 2019 - Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis N. Chen and Others; Original Article Sep 12, 2019 Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Cited by: 7

Author: Joshua Kaplan

Publish Year: 2019

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in ...

<https://www.sciencedirect.com/science/article/pii/S0272638616000056>

Jun 01, 2016 - Of roxadustat-treated participants, 26 of 108 (24.1%) had at least 1 SAE. The only SAE considered as possibly related to roxadustat treatment was acute pancreatitis, diagnosed 2 days after the patient completed 43 days of treatment.

Roxadustat for the treatment of erythropoietin-hyporesponsive ane



ALL

IMAGES

VIDEOS

111,000 Results

Any time ▾

Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901713>

Jul 24, 2019 · Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that **stimulates erythropoiesis** and **regulates iron metabolism**. Additional ...

Cited by: 89

Author: Nan Chen, Chuanming Hao, Bi-Cheng Li...

Publish Year: 2019

Roxadustat for Anemia in Patients with Kidney Disease Not ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1813599>

Jul 24, 2019 · **Roxadustat** and **Anemia** of Chronic Kidney Disease J. Kaplan; Original Article Sep 12, 2019 **Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis** ...

Cited by: 113

Author: Nan Chen, Chuanming Hao, Xiaomei Pe...

Publish Year: 2019

Roxadustat for Anemia in Patients with Chronic Kidney ...

<https://www.nejm.org/doi/full/10.1056/NEJMc1913712>

To the Editor: **Chen et al.** (Sept. 12 issue) 1 report that in their trial of roxadustat (**FGCL-4592-808**) in patients with chronic kidney disease who were not undergoing dialysis, roxadustat was more...

Roxadustat Demonstrates Non-Inferiority to Darbepoetin in ...

<https://finance.yahoo.com/news/roxadustat...> ▾

Jun 08, 2020 · 1 Clinicaltrials.gov. **Roxadustat** in the **Treatment** of **Anemia** in Chronic Kidney Disease

ALL IMAGES VIDEOS MAPS NEWS SHOPPING

104,000 Results Any time ▾

Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901713>

Jul 24, 2019 · Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that **stimulates erythropoiesis** and **regulates iron metabolism**. Additional ...

Cited by: 94 **Author:** Nan Chen, Chuanming Hao, Bi-Cheng Li...

Publish Year: 2019

Roxadustat for Anemia in Patients with Kidney Disease Not ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1813599>

Jul 24, 2019 · **Roxadustat** and **Anemia** of Chronic Kidney Disease J. Kaplan; Original Article Sep 12, 2019 **Roxadustat Treatment for Anemia** in Patients Undergoing Long-Term **Dialysis** ...

Cited by: 119 **Author:** Nan Chen, Chuanming Hao, Xiaomei Pe...

Publish Year: 2019

Roxadustat in the Treatment of Anemia in Chronic Kidney ...

<https://clinicaltrials.gov/ct2/show/NCT01887600> ▾

Jun 27, 2013 · This study was conducted to treat **anemia** in patients with chronic kidney disease. **Anemia** is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if **Roxadustat** is both effective and safe as a **treatment** for **anemia** in patients with chronic kidney ...

Roxadustat Treatment for Anemia in Patients Undergoing ...

<https://www.researchgate.net/publication/334665895...>

Background: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates **iron metabolism**. Additional data are needed regarding the...


Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in ...

[https://www.ajkd.org/article/S0272-6386\(16\)00005-6/fulltext](https://www.ajkd.org/article/S0272-6386(16)00005-6/fulltext)

Of **roxadustat**-treated participants, 26 of 108 (24.1%) had at least 1 SAE. The only SAE considered as possibly related to **roxadustat treatment** was acute pancreatitis, diagnosed 2 days after the **patient** completed 43 days of **treatment**.

Roxadustat

Drug



Roxadustat is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia secondary to chronic kidney

disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs, as it has already been detected being used illicitly by athletes despite not having yet been approved for medical use. Roxadustat received its first global approval in China on 17 December 2018 for the treatment of anaemia caused by CKD in patients who are dialysis-dependent. Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth and also is considered to cause pulmonary hypertension. Recently, in phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.

 Wikipedia

Data from: Wikipedia

[Suggest an edit](#)